Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2020

01-12-2020 | Cholangiocarcinoma | Primary research

Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma

Authors: Zijian Da, Long Gao, Gang Su, Jia Yao, Wenkang Fu, Jinduo Zhang, Xu Zhang, Zhaoji Pei, Ping Yue, Bing Bai, Yanyan Lin, Wenbo Meng, Xun Li

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

Cholangiocarcinoma (CCA) is an invasive malignancy arising from biliary epithelial cells; it is the most common primary tumour of the bile tract and has a poor prognosis. The aim of this study was to screen prognostic biomarkers for CCA by integrated multiomics analysis.

Methods

The GSE32225 dataset was derived from the Gene Expression Omnibus (GEO) database and comprehensively analysed by using R software and The Cancer Genome Atlas (TCGA) database to obtain the differentially expressed RNAs (DERNAs) associated with CCA prognosis. Quantitative isobaric tags for relative and absolute quantification (iTRAQ) proteomics was used to screen differentially expressed proteins (DEPs) between CCA and nontumour tissues. Through integrated analysis of DERNA and DEP data, we obtained candidate proteins APOF, ITGAV and CASK, and immunohistochemistry was used to detect the expression of these proteins in CCA. The relationship between CASK expression and CCA prognosis was further analysed.

Results

Through bioinformatics analysis, 875 DERNAs were identified, of which 10 were associated with the prognosis of the CCA patients. A total of 487 DEPs were obtained by using the iTRAQ technique. Comprehensive analysis of multiomics data showed that CASK, ITGAV and APOF expression at both the mRNA and protein levels were different in CCA compared with nontumour tissues. CASK was found to be expressed in the cytoplasm and nucleus of CCA cells in 38 (45%) of 84 patients with CCA. Our results suggested that patients with positive CASK expression had significantly better overall survival (OS) and recurrence-free survival (RFS) than those with negative CASK expression. Univariate and multivariate analyses demonstrated that negative expression of CASK was a significantly independent risk factor for OS and RFS in CCA patients.

Conclusions

CASK may be a tumour suppressor; its low expression is an independent risk factor for a poor prognosis in CCA patients, and so it could be used as a clinically valuable prognostic marker.
Appendix
Available only for authorised users
Literature
1.
2.
Borbath I, Ceratti A, Verslype C, Demols A, Delaunoit T, Deleporte A, et al. Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology. J Clin Oncol. 2011;29(4_suppl):245.CrossRef
3.
Gaudig I, Schwoerer H, Ramadori G. Treatment of cholangiocarcinoma: retrospective analysis of a single-center experience. J Clin Oncol. 2012;30(4_suppl):376.CrossRef
4.
Suh KS, Roh HR, Koh YT, Lee KU, Park YH, Kim SW. Clinicopathologic features of the intraductal growth type of peripheral cholangiocarcinoma. Hepatology. 2000;31(1):12–7.PubMedCrossRef
5.
Hatzaras I, Choti MA, Schulick RD, Alexandrescu S, Pulitano C, Clary BM, et al. Patterns of recurrence after resection of intrahepatic cholangiocarcinoma: results from a multi-institutional cohort of 449 patients. J Clin Oncol. 2012;30(4_suppl):267.CrossRef
6.
Park J, Kim M, Kim J, Lee J. Survival time and its prognostic factors in advanced unresected cholangiocarcinoma without chemoradiation. J Clin Oncol. 2009;27(15_suppl):e15681.CrossRef
7.
Mosnier JF, Kandel C, Cazals-Hatem D, Bou-Hanna C, Gournay J, Jarry A, et al. N-cadherin serves as diagnostic biomarker in intrahepatic and perihilar cholangiocarcinomas. Mod Pathol. 2009;22(2):182–90.PubMedCrossRef
8.
9.
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 2000;95(1):204–7.PubMedCrossRef
10.
Wang Y, Li J, Xia Y, Gong R, Wang K, Yan Z, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy. J Clin Oncol. 2013;31(9):1188–95.PubMedCrossRef
11.
Hatzaras I, Schmidt C, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Elevated CA 19-9 portends poor prognosis in patients undergoing resection of biliary malignancies. HPB (Oxford). 2010;12(2):134–8.PubMedPubMedCentralCrossRef
12.
Gardini A, Corti B, Fiorentino M, Altimari A, Ercolani G, Grazi GL, et al. Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. Dig Liver Dis. 2005;37(4):269–74.PubMedCrossRef
13.
Bonney GK, Craven RA, Prasad R, Melcher AF, Selby PJ, Banks RE. Circulating markers of biliary malignancy: opportunities in proteomics? Lancet Oncol. 2008;9(2):149–58.PubMedCrossRef
14.
Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot. 2006;57(7):1501–8.PubMedCrossRef
15.
Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829–40.PubMedCrossRef
16.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.PubMedPubMedCentralCrossRef
17.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.CrossRef
18.
Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13.CrossRef
19.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.PubMedPubMedCentralCrossRef
20.
Singh S, Tang S-J, Sreenarasimhaiah J, Lara LF, Siddiqui A. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci. 2011;56(8):2491–6.PubMedCrossRef
21.
Yan XQ, Zhang W, Zhang BX, Liang HF, Zhang WG, Chen XP. Inactivation of Smad4 is a prognostic factor in intrahepatic cholangiocarcinoma. Chin Med J (Engl). 2013;126(16):3039–43.PubMed
22.
Tang Z, Yang Y, Zhang J, Fu W, Lin Y, Su G, et al. Quantitative Proteomic Analysis and Evaluation of the Potential Prognostic Biomarkers in Cholangiocarcinoma. J Cancer. 2019;10(17):3985–99.PubMedPubMedCentralCrossRef
23.
24.
25.
Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, et al. Multi-omics integration analysis robustly predicts high-grade patient survival and identifies CPT1B effect on fatty acid metabolism in bladder cancer. Clin Cancer Res. 2019;25(12):3689–701.PubMedCrossRefPubMedCentral
26.
Lu D-Y, Qu R-X, Lu T-R, Wu H-Y. Cancer bioinformatics for updating anticancer drug developments and personalized therapeutics. Rev Recent Clin Trials. 2017;12(2):101–10.PubMedCrossRef
27.
Zhang C, Zhang B, Meng D, Ge C. Comprehensive analysis of DNA methylation and gene expression profiles in cholangiocarcinoma. Cancer Cell Int. 2019;19(1):352.PubMedPubMedCentralCrossRef
28.
Shen H, Zhang J, Zhang Y, Feng Q, Wang H, Li G, et al. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway. Gene. 2019;698:50–60.PubMedCrossRef
29.
Wang H, Chen H, Jiang Z, Lin Y, Wang X, Xiang J, et al. Integrin subunit alpha V promotes growth, migration, and invasion of gastric cancer cells. Pathol Res Pract. 2019;215(9):152531.PubMedCrossRef
30.
Logan NJ, Camman M, Williams G, Higgins CA. Demethylation of ITGAV accelerates osteogenic differentiation in a blast-induced heterotopic ossification in vitro cell culture model. Bone. 2018;117:149–60.PubMedPubMedCentralCrossRef
31.
Waisberg J, De Souza Viana L, Affonso Junior RJ, Silva SRM, Denadai MVA, Margeotto FB, et al. Overexpression of the ITGAV gene is associated with progression and spread of colorectal cancer. Anticancer Res. 2014;34(10):5599–607.PubMed
32.
Kang CL, Qi B, Cai QQ, Fu LS, Yang Y, Tang C, et al. LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription. Theranostics. 2019;9(15):4421–36.PubMedPubMedCentralCrossRef
33.
Viana LS, Affonso RJ, Silva SR, Denadai MV, Matos D, Souza C, et al. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. Oncology. 2013;84(2):81–91.CrossRef
34.
Lee YS, Lee CH, Bae JT, Nam KT, Moon DB, Hwang OK, et al. Inhibition of skin carcinogenesis by suppression of NF-κB dependent ITGAV and TIMP-1 expression in IL-32γ overexpressed condition. J Exp Clin Cancer Res. 2018;37(1):293.PubMedPubMedCentralCrossRef
35.
Wang X, Driscoll DM, Morton RE. Molecular cloning and expression of lipid transfer inhibitor protein reveals its identity with apolipoprotein F. J Biol Chem. 1999;274(3):1814–20.PubMedCrossRef
36.
Lagor WR, Brown RJ, Toh S-A, Millar JS, Fuki IV, de la Llera-Moya M, et al. Overexpression of apolipoprotein F reduces HDL cholesterol levels in vivo. Arterioscler Thromb Vasc Biol. 2009;29(1):40–6.PubMedCrossRef
37.
Morton RE, Liu Y, Izem L. ApoF knockdown increases cholesteryl ester transfer to LDL and impairs cholesterol clearance in fat-fed hamsters. J Lipid Res. 2019;60(11):1868–79.PubMedCrossRefPubMedCentral
38.
Wang YB, Zhou BX, Ling YB, Xiong ZY, Li RX, Zhong YS, et al. Decreased expression of ApoF associates with poor prognosis in human hepatocellular carcinoma. Gastroenterol Rep (Oxf). 2019;7(5):354–60.PubMedPubMedCentralCrossRef
39.
Wang Q, Lu J, Yang C, Wang X, Cheng L, Hu G, et al. CASK and its target gene Reelin were co-upregulated in human esophageal carcinoma. Cancer Lett. 2002;179(1):71–7.PubMedCrossRef
40.
Dimitratos SD, Woods DF, Bryant PJ. Camguk, Lin-2, and CASK: novel membrane-associated guanylate kinase homologs that also contain CaM kinase domains. Mech Dev. 1997;63(1):127–30.PubMedCrossRef
41.
Hsueh YP, Yang FC, Kharazia V, Naisbitt S, Cohen AR, Weinberg RJ, et al. Direct interaction of CASK/LIN-2 and syndecan heparan sulfate proteoglycan and their overlapping distribution in neuronal synapses. J Cell Biol. 1998;142(1):139–51.PubMedPubMedCentralCrossRef
42.
LaConte LEW, Chavan V, Liang C, Willis J, Schönhense E-M, Schoch S, et al. CASK stabilizes neurexin and links it to liprin-α in a neuronal activity-dependent manner. Cell Mol Life Sci. 2016;73(18):3599–621.PubMedPubMedCentralCrossRef
43.
Gardner KL, Sanford JL, Mays TA, Rafael-Fortney JA. CASK localizes to nuclei in developing skeletal muscle and motor neuron culture models and is agrin-independent. J Cell Physiol. 2006;206(1):196–202.PubMedCrossRef
44.
Gao R, Piguel NH, Melendez-Zaidi AE, Martin-de-Saavedra MD, Yoon S, Forrest MP, et al. CNTNAP2 stabilizes interneuron dendritic arbors through CASK. Mol Psychiatry. 2018;23(9):1832–50.PubMedPubMedCentralCrossRef
45.
Akrami H, Moradi B, Borzabadi Farahani D, Mehdizadeh K. Ibuprofen reduces cell proliferation through inhibiting Wnt/β catenin signaling pathway in gastric cancer stem cells. Cell Biol Int. 2018;42(8):949–58.PubMedCrossRef
46.
Zhou X, Xu G, Yin C, Jin W, Zhang G. Down-regulation of miR-203 induced by Helicobacter pylori infection promotes the proliferation and invasion of gastric cancer by targeting CASK. Oncotarget. 2014;5(22):11631–40.PubMedPubMedCentralCrossRef
47.
Wei JL, Fu ZX, Fang M, Zhou QY, Zhao QN, Guo JB, et al. High expression of CASK correlates with progression and poor prognosis of colorectal cancer. Tumour Biol. 2014;35(9):9185–94.PubMedCrossRef
48.
Márquez-Rosado L, Singh D, Rincón-Arano H, Solan JL, Lampe PD. CASK (LIN2) interacts with Cx43 in wounded skin and their coexpression affects cell migration. J Cell Sci. 2012;125(Pt 3):695–702.PubMedPubMedCentralCrossRef
Metadata
Title
Bioinformatics combined with quantitative proteomics analyses and identification of potential biomarkers in cholangiocarcinoma
Authors
Zijian Da
Long Gao
Gang Su
Jia Yao
Wenkang Fu
Jinduo Zhang
Xu Zhang
Zhaoji Pei
Ping Yue
Bing Bai
Yanyan Lin
Wenbo Meng
Xun Li
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01212-z

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue

Primary research

ZBTB7A, a potential biomarker for prognosis and immune infiltrates, inhibits progression of endometrial cancer based on bioinformatics analysis and experiments

Primary research

The fiber metabolite butyrate reduces gp130 by targeting TRAF5 in colorectal cancer cells

Primary research

SFRP1 increases TMPRSS2-ERG expression promoting neoplastic features in prostate cancer in vitro and in vivo

Primary research

Bioinformatics profiling integrating a three immune-related long non-coding RNA signature as a prognostic model for clear cell renal cell carcinoma

Primary research

A novel mechanism by which ACTA2-AS1 promotes cervical cancer progression: acting as a ceRNA of miR-143-3p to regulate SMAD3 expression

Primary research

Circ_0015756 promotes the progression of ovarian cancer by regulating miR-942-5p/CUL4B pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits